Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma

被引：9
|
作者：
Hindie, Elif [1 ]
机构：
[1] Bordeaux Univ Hosp, Bordeaux, France
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2021年 / 385卷 / 03期
关键词：
SUNITINIB;
D O I：
10.1056/NEJMc2107518
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：287 / 287
页数：1
相关论文
共 50 条
  • [1] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert
    Alekseev, Boris
    Rha, Sun-Young
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Kopyltsov, Evgeny
    Mendez-Vidal, Maria J.
    Kozlov, Vadim
    Alyasova, Anna
    Hong, Sung-Hoo
    Kapoor, Anil
    Alonso Gordoa, Teresa
    Merchan, Jaime R.
    Winquist, Eric
    Maroto, Pablo
    Goh, Jeffrey C.
    Kim, Miso
    Gurney, Howard
    Patel, Vijay
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Melichar, Bohuslav
    Rolland, Frederic
    De Giorgi, Ugo
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Dutcus, Corina E.
    Smith, Alan D.
    Dutta, Lea
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing, Dongyuan
    Choueiri, Toni K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14): : 1289 - 1300
  • [2] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Mathew
    Stepan, Daniel E.
    Shumaker, Robert
    Schmidt, Emmett V.
    Guo, Matthew
    Dutcus, Corina
    Young, Louise
    Motzer, Robert
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 175
  • [3] Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2021, 206 (06): : 1518 - 1519
  • [4] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [5] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [6] New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma
    Saillant, Arnaud
    Borchiellini, Delphine
    [J]. BULLETIN DU CANCER, 2022, 109 (7-8) : 737 - +
  • [7] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results.
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew W.
    Taylor, Matthew H.
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Schmidt, Emmett V.
    Guo, Matthew
    Dutcus, Corina E.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
    Ged, Yasser
    Lee, Chung-Han
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1049 - 1059
  • [9] Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population
    Fujiwara, Ryo
    Yuasa, Takeshi
    Kobayashi, Kenichi
    Yoshida, Tetsuya
    Kageyama, Susumu
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (05) : 461 - 469
  • [10] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Matthew
    Dutcus, Corina
    Shumaker, Robert
    Schmidt, Emmett
    Stepan, Daniel E.
    Li, Di
    Young, Louise
    Motzer, Robert
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
12345